Literature DB >> 9480870

Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation.

M V Vinogradova1, L Michaud, A V Mezentsev, K E Lukong, M El-Alfy, C R Morales, M Potier, A V Pshezhetsky.   

Abstract

Galactosialidosis is an inherited lysosomal storage disease caused by the combined deficiency of lysosomal sialidase and beta-galactosidase secondary to the deficiency of cathepsin A/protective protein, which is associated with sialidase and beta-galactosidase in a high-molecular weight (1.27MDa) complex. Clinical phenotypes of patients as well as the composition of compounds which are stored in patient's tissues implicate sialidase deficiency as the underlying pathogenic defect. The recent cloning and sequencing of lysosomal sialidase [Pshezhetsky, Richard, Michaud, Igdoura, Wang, Elsliger, Qu, Leclerc, Gravel, Dallaire and Potier (1997), Nature Genet. 15, 316-320] allowed us to study the molecular mechanism of sialidase deficiency in galactosialidosis. By Western blotting, using antibodies against the recombinant human enzyme, and by NH2-terminal sequencing, we showed that sialidase is synthesized as a 45.5 kDa precursor and after the cleavage of the 47-amino acid signal peptide and glycosylation becomes a 48.3 kDa mature active enzyme present in the 1.27 kDa complex. Transgenic expression of sialidase in cultured skin fibroblasts from normal controls and from galactosialidosis patients, followed by immunofluorescent and immunoelectron microscopy showed that in both normal and affected cells the expressed sialidase was localized on lysosomal and plasma membranes, but the amount of sialidase found in galactosialidosis cells was approximately 5-fold reduced. Metabolic labelling studies demonstrated that the 48.3 kDa mature active form of sialidase was stable in normal fibroblasts (half-life approximately 2.7 h), whereas in galactosialidosis fibroblasts the enzyme was rapidly converted (half-life approximately 30 min) into 38.7 and 24 kDa catalytically inactive forms. Altogether our data provide evidence that the molecular mechanism of sialidase deficiency in galactosialidosis is associated with abnormal proteolytic cleavage and fast degradation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9480870      PMCID: PMC1219185          DOI: 10.1042/bj3300641

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  40 in total

1.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.

Authors:  M Potier; L Mameli; M Bélisle; L Dallaire; S B Melançon
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

2.  Two species of lysosomal organelles in cultured human fibroblasts.

Authors:  L H Rome; A J Garvin; M M Allietta; E F Neufeld
Journal:  Cell       Date:  1979-05       Impact factor: 41.582

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Purification of acid beta-galactosidase and acid neuraminidase from bovine testis: evidence for an enzyme complex.

Authors:  F Verheijen; R Brossmer; H Galjaard
Journal:  Biochem Biophys Res Commun       Date:  1982-09-30       Impact factor: 3.575

5.  Purification and partial characterization of lysosomal neuraminidase from human placenta.

Authors:  F W Verheijen; S Palmeri; H Galjaard
Journal:  Eur J Biochem       Date:  1987-01-02

6.  Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function.

Authors:  N J Galjart; H Morreau; R Willemsen; N Gillemans; E J Bonten; A d'Azzo
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

7.  The relation between human lysosomal beta-galactosidase and its protective protein.

Authors:  A T Hoogeveen; F W Verheijen; H Galjaard
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

8.  Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man.

Authors:  A D'Azzo; A Hoogeveen; A J Reuser; D Robinson; H Galjaard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

9.  Human placental neuraminidase. Activation, stabilization and association with beta-galactosidase and its protective protein.

Authors:  F W Verheijen; S Palmeri; A T Hoogeveen; H Galjaard
Journal:  Eur J Biochem       Date:  1985-06-03

10.  Immunocytochemical identification of phenylalanine hydroxylase and albumin in cultured hepatoma cells and isolated rat hepatocytes.

Authors:  R E Baker; L S Jefferson; R Shiman
Journal:  J Cell Biol       Date:  1981-07       Impact factor: 10.539

View more
  18 in total

1.  LPS-induced cytokine production in human dendritic cells is regulated by sialidase activity.

Authors:  Nicholas M Stamatos; Ivan Carubelli; Diantha van de Vlekkert; Erik J Bonten; Nadia Papini; Chiguang Feng; Bruno Venerando; Alessandra d'Azzo; Alan S Cross; Lai-Xi Wang; Peter J Gomatos
Journal:  J Leukoc Biol       Date:  2010-09-08       Impact factor: 4.962

Review 2.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

Review 3.  Where catabolism meets signalling: neuraminidase 1 as a modulator of cell receptors.

Authors:  Alexey V Pshezhetsky; Aleksander Hinek
Journal:  Glycoconj J       Date:  2011-09-20       Impact factor: 2.916

4.  A mutation map for human glycoside hydrolase genes.

Authors:  Lars Hansen; Diab M Husein; Birthe Gericke; Torben Hansen; Oluf Pedersen; Mitali A Tambe; Hudson H Freeze; Hassan Y Naim; Bernard Henrissat; Hans H Wandall; Henrik Clausen; Eric P Bennett
Journal:  Glycobiology       Date:  2020-07-16       Impact factor: 4.313

5.  Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.

Authors:  Erik J Bonten; Yvan Campos; Viateslav Zaitsev; Amanda Nourse; Brett Waddell; William Lewis; Garry Taylor; Alessandra d'Azzo
Journal:  J Biol Chem       Date:  2009-08-07       Impact factor: 5.157

Review 6.  Recent development in mammalian sialidase molecular biology.

Authors:  Eugenio Monti; Augusto Preti; Bruno Venerando; Giuseppe Borsani
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

7.  Cell-permeable probe for identification and imaging of sialidases.

Authors:  Charng-Sheng Tsai; Hsin-Yung Yen; Meng-I Lin; Tsung-I Tsai; Shi-Yun Wang; Wen-I Huang; Tsui-Ling Hsu; Yih-Shyun E Cheng; Jim-Min Fang; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

8.  Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.

Authors:  Aleksander Hinek; Tetyana D Bodnaruk; Severa Bunda; Yanting Wang; Kela Liu
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

9.  Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease.

Authors:  Yong Hong Chen; Kristin Claflin; James C Geoghegan; Beverly L Davidson
Journal:  Mol Ther       Date:  2012-05-15       Impact factor: 11.454

Review 10.  Exploration of the Sialic Acid World.

Authors:  Roland Schauer; Johannis P Kamerling
Journal:  Adv Carbohydr Chem Biochem       Date:  2018-11-28       Impact factor: 12.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.